Therapeutic response to metformin, a first-line drug for type 2 diabetes (T2D), is highly variable, in part likely due to genetic factors. To date, metformin pharmacogenetic studies have mainly focused on the impact of variants in metformin transporter genes, with inconsistent results. To clarify the significance of these variants in glycemic response to metformin in T2D, we performed a large-scale meta-analysis across the cohorts of the Metformin Genetics Consortium (MetGen). Nine candidate polymorphisms in five transporter genes (organic cation transporter [OCT]1, OCT2, multidrug and toxin extrusion transporter [MATE]1, MATE2-K, and OCTN1) were analyzed in up to 7,968 individuals. None of the variants showed a significant effect on metformin response in the primary analysis, or in the exploratory secondary analyses, when patients were stratified according to possible confounding genotypes or prescribed a daily dose of metformin. Our results suggest that candidate transporter gene variants have little contribution to variability in glycemic response to metformin in T2D.
common genetic variants, each conferring a small to moderate impact. 3 As a result, a large sample size is required for pharmacogenetic studies aiming to discover these common metformin response variants.
Previously published studies of metformin pharmacogenetics have mostly focused on the candidate genes involved in drug pharmacokinetics, with the expectation that these might have a large clinical effect. For example, polymorphisms in the transporters, organic anion-transporting polypeptide 1B1 and breast cancer resistance protein, have been associated with large effect sizes with the pharmacokinetics and pharmacodynamics of several drugs, including statins. 4 Metformin is not metabolized and is excreted unchanged by the kidneys. Its primary mode of action seems to be an increase of hepatic insulin sensitivity through inhibition of gluconeogenesis, 5 although there is increasing recognition of its role in the gut. 6 As metformin is an organic cation at physiologic pH, cation-selective carrier proteins mediate its transport across cell membranes in the intestine, liver, and kidneys. Organic cation transporter 1 (OCT1; encoded by SLC22A1) is expressed on the sinusoidal membrane of hepatocytes and is the main transporter of metformin into the liver. 7 Organic cation transporter 2 (OCT2; encoded by SLC22A2) is expressed primarily at the basolateral membrane in the kidney tubular cells and facilitates the uptake of metformin from the blood into the kidneys. 8 The multidrug and toxin extrusion transporter 1 (MATE1; encoded by SLC47A1) and MATE2-K (encoded by SLC47A2), are H 1 /drug antiporters located in the apical membrane of the renal tubular cells, and facilitate metformin excretion from tubular cells into urine. [9] [10] [11] A recent study showed that metformin is also a substrate of carnitine/cation transporter 1 (OCTN1; encoded by SLC22A4). 12 OCTN1 is highly expressed at the apical membranes in renal proximal tubules and could also contribute to metformin elimination. 13, 14 To date, several polymorphisms in these transporter genes have been associated with the pharmacokinetics and pharmacodynamics of metformin in healthy volunteers [15] [16] [17] [18] and with metformin response in T2D. [18] [19] [20] [21] [22] [23] [24] [25] In addition, a few studies have reported gene-gene interactions between polymorphisms in transporter genes. 18, 22, 26 However, the results of these studies have been inconsistent and the impact of the established pharmacokinetic variants on metformin clinical response in T2D is uncertain. 27 Apart from the different measures of glycemic response used in these studies, the small sample size and reporting bias is another potential explanation for the observed inconsistency.
To clarify the role of genetic variants in these transporters on metformin clinical response, we performed a large-scale metaanalysis of the impact of known candidate variants on metformin efficacy in T2D, across the cohorts of recently established Metformin Genetics Consortium (MetGen). This resource now has in excess of 10,000 individuals in whom metformin response can be defined, and offers a unique opportunity for a highly powered pharmacogenetic meta-analysis of glycemic response to metformin.
RESULTS
We studied the effect of nine candidate variants in transporter genes OCT1, 15, 16, 19, 20, 23, 28 OCT2, 17, 23, 25, 29, 30 MATE1, 18, 21, 23, 25, 28, 31 MATE2-K, 18, 24 and OCTN1 14, 28 (Table 1 ) on metformin glycemic response in 7,968 MetGen participants of European ancestry. Of these, the definition of metformin response could be aligned for a meta-analysis in 7,656 participants, of whom 5,836 were initiated on metformin monotherapy and 1,820 were initiated on metformin as add-on treatment for sulfonylureas (dual therapy; Table 2 ). Forest plots for the meta-analyses of the individual variants in the monotherapy group are presented in Figure 1 . There was no significant heterogeneity between the studies for any polymorphism. None of the variants was significantly associated with glycemic response to metformin ( Figure 1) . Similarly, when patients on monotherapy and dual therapy were analyzed together, no single-nucleotide polymorphism (SNP) showed significant association with HbA 1c reduction ( Supplementary Table S1 online). The results from the HOME and SDDS studies, two MetGen cohorts in which metformin was added to insulin therapy, did not show significant impact on metformin response assessed as HbA 1c reduction ( Supplementary Table S2 online). As the transport of metformin could depend on its concentration, we next explored possible gene by dose interactions, using a dose as a proxy of metformin concentration. In the meta-analysis of SNP 3 dose interaction effects, none of the interactions showed significant effect in the monotherapy group (Table 3) or the total group when patients on dual therapy were added to the analysis ( Supplementary Table S3a online). Likewise, no significant associations were found in the separate meta-analyses of the effects of variants on metformin response in individuals treated with low (1,000 mg) or high daily doses of metformin (>1,000 mg; Table 4 and Supplementary Table S3b online).
We next explored the potential interactions between these transporters that might affect metformin response. The interactions were tested by examining the impact of one SNP in two separate subgroups of participants, homozygotes for the reference, and variant allele of a potential confounding SNP. Tables 5a and 5b show the results from meta-analyses of participants on monotherapy for transporters in the liver and kidneys, respectively. Supplementary Tables S4a and S4b online show the meta-analyses results for all participants, including both monotherapy and dual therapy. These exploratory subgroup analyses revealed no significant interactions between the SNPs that affect metformin glycemic response.
In the supplemental locus-wise meta-analysis of the association of all common SNPs in transporter gene regions with metformin glycemic response, none of the variants showed significant signal after correction for multiple testing (P > 1.6 3 10 24 ; Supplementary Figure S1 ).
DISCUSSION
Despite the established role of cation-selective transporters in metformin pharmacokinetics, polymorphisms in these transporters showed no significant impact on glycemic response to metformin in this large study of patients with T2D. This meta-analysis had 80% power to detect an allelic effect of HbA 1c reduction >0.14% (1.5 mmol/mol) for any of the candidate SNPs at the nominal significance level of a 5 0.005. Thus, none of the SNPs reported as being associated with metformin response in previous literature is likely to have an allelic impact on HbA 1c reduction of >0.14%. Furthermore, it is unlikely that other SNPs, such as cis-regulatory variants, in these genes could have a significant impact on metformin glycemic response, as shown by a locuswise meta-analysis of all common SNPs within genes' proximity in 6,964 patients.
Our findings contrast to most of those previously reported in healthy subjects, [15] [16] [17] [18] although it is in keeping with a recent study showing no impact of the OCT1 genotype on the glucose production in fasting healthy subjects. 32 This may reflect the fact that our study was conducted on patients with T2D and, as such, we were able to assess HbA 1c reduction rather than other surrogates of metformin response. Some 18, 20, 21, [23] [24] [25] but not all 19 previous studies have reported an association of a variant altering metformin transport and glycemic response to metformin in patients with T2D. These studies have varied in size but have generally been small, and have varied in their definition of glycemic response to metformin and analytical approaches. In this MetGen meta-analysis, we included all studies that have previously explored associations between transporter variants and glycemic response to metformin in patients with T2D of European ancestry with both positive and negative findings, [18] [19] [20] [21] [22] [23] [24] [25] and also other cohorts for which results have not been published. In this way, we have reduced the chance of reporting bias and maximized the power. In addition, we have reduced heterogeneity by aligning metformin response definitions, models, and covariates for all studies included in the meta-analysis. Our results suggest that metformin transporters do not have a significant role in how patients with T2D respond to metformin therapy. Transporters exhibit asymmetry in their kinetic properties; thus, for facilitated transporters that are bidirectional, the direction of the transport will depend on the substrate concentration. 33, 34 Systemic plasma levels of metformin are dependent on dose; therefore, in our secondary analyses, we analyzed dose 3 SNP interactions and assessed the effect of the studied variants separately in individuals prescribed low (1,000 mg) or high (>1,000 mg) doses of the drug. We did not find significant impact of the analyzed interactions on metformin glycemic response, and, accordingly, significant association between any variant and response in the dose-stratified analysis. However, we used the prescribed dose as a proxy of metformin concentration. There were differences in the characteristics of patients between the cohorts, and, for instance, older age and lower estimated glomerular filtration rate in the Rotterdam cohort could result in higher metformin serum levels, despite being prescribed lower doses. In addition, data on drug adherence were available only in four studies, although all studies were adjusted for creatinine clearance and other known clinical covariates, which could influence metformin response.
Studies of small cohorts have previously reported gene-gene interactions affecting glycemic response to metformin. 18, 22 Here, we explored whether such interactions could explain the lack of association between metformin response and transporter variants. The exploratory analyses of SNP 3 SNP interactions, assessed as the impact of studied polymorphisms on metformin response in the subgroups of patients homozygous for possibly confounding SNPs, did not show any significant effects. However, these subgroup analyses had substantially less power to detect moderate effects due to the smaller sample sizes, especially for the rarer SNPs. Larger studies would be needed to detect these effects and to explore possible but more complex multiple gene-gene interactions. This is the largest metformin pharmacogenetic study reported to date, despite a few limitations due to the need to align cohorts. Our finding that there is no significant role for metformin transporter variants in mediating glycemic response to metformin challenges our understanding of metformin action in patients with T2D chronically treated with metformin. For example, there is increasing recognition that metformin works presystemically in the gut, via a number of mechanisms, to improve glycemia. 6, [35] [36] [37] Indeed, a recent delayed release metformin achieves low systemic metformin concentrations but is effective at lowering blood glucose in patients with T2D. 38 It is also possible that the influence of the analyzed transporter gene variants is less prominent clinically than expected due to the redundancy of transporters in vivo. 27 If one or more transporters have reduced function, other transporters may take over their roles and mediate metformin uptake or efflux from the organs. In addition, there might be more membrane transporters of metformin yet to be identified that could have a role in its absorption, distribution, and elimination. In the current study, we focused on the candidate variants in the membrane transporter genes that have been associated previously with metformin pharmacokinetics or response. However, in addition to liver and kidney transporters, transporters in the intestine may play a significant role in metformin levels. Recent studies have suggested that other transporters, which were not the subject of this study, play an important role in metformin absorption, 34, [39] [40] [41] and there still may be unidentified cation transporters in the intestine involved in metformin absorption, which could also affect metformin response. It should also be noted that variants in transporters in various tissues may play opposing roles. For example, OCT1 could mediate basolateral flux of metformin from enterocytes to the portal circulation 7, 42 and across the sinusoidal membrane of hepatocytes. 7 Thus, a reduced function OCT1 genetic variant may result in increased concentrations in enterocytes and decreased concentrations in hepatocytes. 
ARTICLES
Although the current study demonstrates that genetic variants in transporters that play a role in metformin pharmacokinetics have no significant effect on metformin glycemic response in large cohorts of patients with diabetes, there are some limitations to our study. First, despite the large sample size used in the current study, we did not have the statistical power to detect an allelic effect size for HbA 1c reduction smaller than 0.06-0.14% (0.7-1.5 mmol/mol, depending on SNP frequency), however, these small effect sizes may be unlikely to have any clinical importance. Second, the meta-analysis included population-based observational studies, which could be confounded by a number of factors, such as patient adherence or frequency of HbA 1c measurements in the cohort. However, in four cohorts, including two largest cohorts, GoDARTS and PMT2-EU, adherence could be calculated from the drug dispensing records, and was added as a covariate in the model. Likewise, although we could not completely harmonize the definition of on-treatment HbA 1c due to different frequency of HbA 1c measurements available in the cohorts, four studies, including two of the largest studies, used minimal HbA 1c achieved within 18 months as outcome. Third, concomitant medications, which affect metformin transport, are well established to cause changes in its pharmacokinetics, 43 and may obscure effects of genetic variants on metformin response. Information on prescription and over-the-counter drugs that affect metformin pharmacokinetics, such as cimetidine, were not gathered in the current study. In addition, several previous studies have shown effects of polymorphisms in transporters on metformin response in multi-ethnic cohorts, including many individuals from non-European ancestries. 18, 24 Genetic variants may have different effect sizes on drug response in individuals from different ethnic backgrounds. Further studies are needed to test the effects of these variants on metformin response in individuals from non-European backgrounds. Finally, recent studies suggest that genetic variants in transcription factors that affect expression of several metformin transporters may have larger effect sizes on metformin response than genetic variants in the individual transporters themselves, 44 underscoring the need to understand not only the mechanisms of metformin transport in various tissues, but the proteins that modulate their activity and expression.
In conclusion, in our large meta-analysis, including almost 8,000 individuals across 10 international cohorts of the MetGen Consortium, variants in metformin transporter genes have shown no relevant contribution to variability in metformin response in patients with T2D, although we cannot rule out geneconcentration or more complex multiple gene-gene interactions that may be required to account for transporter redundancy. As has been recognized now for a number of years in disease and complex trait genetics, this study shows the importance of large sample sizes, usually only available to international consortia, for robust pharmacogenetic studies. Future even larger consortia efforts are required to corroborate these findings and to unravel genetic variations that could be used as better predictors for personalized metformin therapy. 

METHODS
Studies
The MetGen Consortium consists of research groups from Europe and the United States with available data for studies of metformin pharmacogenetics from population observational studies and clinical trials. The 10 MetGen cohorts with available data for the study of metformin transporter gene variants are presented in Supplementary Table S5 online. The studies were approved by relevant institutional review boards, and all participants gave written informed consent.
Single-nucleotide polymorphism selection and genotyping Nine SNPs in five transporter genes, reported to be associated with metformin response or pharmacokinetics in previous studies, were included in the meta-analysis ( Table 1 ). The numbers of available SNPs, genotyping methods, and the minor allele frequencies in each cohort are provided in Supplementary Table S6 online. All SNPs were in line with Hardy-Weinberg equilibrium (P > 0.01). The variants were first analyzed individually for association with metformin response. The reduced-function OCT1 polymorphisms, R61C and M420del, were analyzed individually, and also together as a combined genotype, according to the number of haplotypes carrying reduced-function alleles: 0, 1, or 2, in line with previous studies in patients of European ancestry. 23, 45, 46 Assessment of metformin response Metformin response was defined as a reduction in HbA 1c during treatment with metformin: pretreatment minus on-treatment HbA 1c . As such, a positive b in the regression models indicates an association of the effect allele with greater glycemic response to metformin. Inclusion criteria for all participants included in the meta-analysis were continuous treatment with metformin for at least 3 months, pretreatment HbA 1c measured within 6 months prior to metformin therapy and <14%, measurement of on-treatment HbA 1c within 18 months of metformin commencement, and no treatment with other glucose-lowering agents except stable sulfonylurea treatment before and during metformin therapy. Hence, two cohorts from randomized controlled trials, HOME and SDDS studies, in which metformin was added to insulin therapy, were not included in the meta-analysis, and the results are shown separately. On-treatment HbA 1c was defined as minimal HbA 1c measured within 18 months of metformin commencement in the GoDARTS, PMT2-EU, Riga, and Rotterdam studies, as HbA 1c measured after 6 months (Ko sice and Sarajevo studies) or 12 months (DCS study) of metformin treatment, and as HbA 1c measured within the first 3-9 months of metformin therapy in the PMT1-EU study.
Statistical analysis
In each cohort, the effects of individual SNPs on metformin response were assessed in additive genetic model using linear regression with reduction of HbA 1c as outcome (primary analysis). The pretreatment HbA 1c , metformin daily dose, adherence, creatinine clearance, baseline gap (time between pretreatment HbA 1c measurement and start of metformin therapy), and treatment group (metformin prescribed as monotherapy or dual therapy -metformin added to stable sulfonylurea treatment), were added as covariates, when available/applicable (Supplementary Table S7 online). In the HOME study, analyses were adjusted for pretreatment HbA 1c , metformin daily dose and creatinine clearance, and in the SDDS study, pretreatment HbA 1c and randomization group 23 were added as covariates.
As the effects of transporter SNPs could depend on metformin level, or they could be confounded by the effect of other variants, secondary analyses were performed to explore possible gene-dose and gene-gene interactions. For gene-dose interactions, we first examined interaction models that included SNP 3 dose interaction term with dose as a continuous variable and then dose coded as a dichotomized variable (low or high dose) in the following model: HbA 1c reduction pre-treatment HbA 1c 1 adherence 1 creatinine clearance 1 baseline gap 1 treatment group 1 dose 1 SNP 1 SNP 3 dose. Next, we assessed the association of SNPs with metformin response separately for patients taking low (1,000 mg) or high doses (>1,000 mg) of metformin. The cutoff value of 1,000 mg was chosen based on the median dose in the largest cohort. The analyses were performed using the same basic regression model: HbA 1c reduction pre-treatment HbA 1c 1 adherence 1 creatinine clearance 1 baseline gap 1 treatment group 1 dose 1 SNP.
To examine potential interactions between the variants, additional exploratory analyses of the effects of individual SNPs were carried out in the subgroups of individuals who were homozygous for wild-type allele and of the individuals who were homozygous for variant allele of possibly confounding SNPs, assuming that impact of the variants could be more pronounced in more extreme genotype groups. Possible 1 3 1 interactions between SNPs in metformin liver transporters (OCT1 and MATE1), and SNPs in metformin kidney transporters (OCT2, MATE1, MATE2-K, and OCTN1) were explored.
All analyses were carried out for the total group of patients treated with metformin, including monotherapy and dual therapy group (metformin added to stable sulfonylurea therapy), and also separately for the metformin monotherapy group. The results from individual studies were combined in the meta-analysis using PLINK software under fixed-effects model (http://pngu.mgh.harvard.edu/purcell/plink/). 47 For gene-dose interaction models, estimates of SNP 3 dose interaction terms were pooled in the meta-analysis. 48 Heterogeneity across studies was assessed using the Cochran Q test and the I 2 heterogeneity index. In case the substantial heterogeneity was detected (P value for Cochran Q test <0.10), the results of the random-effects model were presented. Power analyses were performed using Quanto (http://biostats.usc.edu/Quanto.html). Forest plots were created using RevMan 5.3 software (Review Manager, The Nordic Cochrane Centre, The Cochrane Collaboration).
As the primary analysis included nine SNPs and one combined OCT1 genotype, a nominal statistical significance threshold was set to 5 3 10 23 (P 5 0.05/10), and a study-wise statistical significance threshold to 2 3 10 24 to correct for the overall number of tests performed (P 5 0.05/236).
In addition to our main hypothesis, we performed a supplemental, locus-wise meta-analysis of all common SNPs within the proximity of the transporter genes to examine the possibility that original associations reported in previous studies might be driven by other SNPs in these gene regions. A total of 3,471 variants with minor allele frequency 1% were tested for association with metformin glycemic response in 6,964 participants from two MetGen cohorts with available genome-wide association study imputed data, the GoDARTS and PMT2-EU. The details of genotyping, quality control, imputation, association analysis, and metaanalysis were described in our previous study. 49 The experiment-wise significance threshold for this supplemental analysis was derived from 10,000 permutations of the phenotype in the GoDARTS data, 47 which gave a 95% cutoff for significance of P 5 1.6 3 10 24 .
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